Compare IT & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IT | MDGL |
|---|---|---|
| Founded | 1979 | 2011 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 11.1B |
| IPO Year | 2010 | 2005 |
| Metric | IT | MDGL |
|---|---|---|
| Price | $133.24 | $534.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $189.25 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 1.4M | 308.2K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ 3.18 | N/A |
| Revenue | ★ $2,021,441,000.00 | $180,133,000.00 |
| Revenue This Year | $3.52 | $58.39 |
| Revenue Next Year | $5.08 | $48.55 |
| P/E Ratio | $41.72 | ★ N/A |
| Revenue Growth | ★ 13.30 | N/A |
| 52 Week Low | $124.25 | $286.75 |
| 52 Week High | $375.84 | $615.00 |
| Indicator | IT | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 54.32 |
| Support Level | $124.25 | $498.59 |
| Resistance Level | $162.80 | $545.29 |
| Average True Range (ATR) | 5.21 | 22.69 |
| MACD | 0.83 | 3.86 |
| Stochastic Oscillator | 48.12 | 46.15 |
Gartner Inc delivers actionable, objective business and technology insights that drive smarter decisions and stronger performance on an organization's mission-critical priorities. It delivers its products and services globally through three reportable segments - Business and Technology Insights, Conferences and Consulting. Insights equips executives and their teams from every Majority function, geography, industry and sector with actionable, objective insights, guidance and tools. Conferences provides executives and teams across an organization the opportunity to learn, share and network. and Consulting serves senior executives technology-driven strategic initiatives leveraging the power of Gartner's actionable, objective insight. The Majority revenue is derived from the Insights segment.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.